PMID- 28464435
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20181202
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 14
IP  - 1
DP  - 2018 Feb
TI  - Management of epidermal growth factor receptor tyrosine kinase inhibitor-related 
      cutaneous and gastrointestinal toxicities.
PG  - 23-31
LID - 10.1111/ajco.12687 [doi]
AB  - Patients with advanced stage non-small cell lung cancer with sensitizing 
      epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase 
      inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line 
      treatment had better progression-free survival, overall response rate and quality 
      of life than those on chemotherapy. Although EGFR TKIs are commonly associated 
      with skin-related (rash, xerosis and paronychia) and gastrointestinal-related 
      (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild. 
      But severe cases can occur, significantly affecting patient's well-being, 
      treatment compliance and quality of life. Therefore, patient education, early 
      diagnosis, and prophylactic treatment are important strategies to optimally 
      manage EGFR TKI-related adverse effects. In this review, we summarize the 
      commonly encountered EGFR TKI-related AEs and provide a current overview of AE 
      management in local practice with a focus on Asian patients.
CI  - (c) 2017 The Authors. Asia-Pacific Journal of Clinical Oncology Published by John 
      Wiley & Sons Australia, Ltd.
FAU - Aw, Derrick Chen-Wee
AU  - Aw DC
AD  - Department of General Medicine, Sengkang Health, Alexandra Hospital, Singapore.
FAU - Tan, Eng Huat
AU  - Tan EH
AD  - Division of Medical Oncology, National Cancer Centre, Singapore.
FAU - Chin, Tan Min
AU  - Chin TM
AD  - Department of Haematology-Oncology, National University Cancer Institute of 
      Singapore, National University Health System, Singapore.
FAU - Lim, Hong Liang
AU  - Lim HL
AD  - Medical Oncology, Parkway Cancer Centre, Singapore.
FAU - Lee, Haur Yueh
AU  - Lee HY
AD  - Department of Dermatology, Singapore General Hospital, Singapore.
FAU - Soo, Ross A
AU  - Soo RA
AD  - Department of Haematology-Oncology, National University Cancer Institute of 
      Singapore, National University Health System, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170502
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/enzymology
MH  - Diarrhea/*chemically induced/*therapy
MH  - Disease-Free Survival
MH  - Drug Eruptions/etiology/*therapy
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Humans
MH  - Lung Neoplasms/drug therapy/enzymology
MH  - Mutation
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Quality of Life
MH  - Stomatitis/*chemically induced/*therapy
OTO - NOTNLM
OT  - adverse drug events
OT  - gastrointestinal tract
OT  - mutations
OT  - non-small cell lung cancer
OT  - skin
EDAT- 2017/05/04 06:00
MHDA- 2018/03/27 06:00
CRDT- 2017/05/03 06:00
PHST- 2016/10/24 00:00 [received]
PHST- 2017/03/03 00:00 [accepted]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/05/03 06:00 [entrez]
AID - 10.1111/ajco.12687 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31. doi: 10.1111/ajco.12687. Epub 2017 
      May 2.